Analysis of histopathological and clinical prognostic factors in lymphomas involving the gastrointestinal system

Table 1 Histologic classification of patients, n (%)

Histologic type	Stomach (n = 75)	Small bowel (n = 20)	Large bowel rectum (n = 14)	Pancreas (n = 2)	Total patients (n = 111)
B-cell lymphoma					106 (95.4)
DLBCL	65 (86.6)	13 (65)	7 (50)	2 (100)
MALT lymphoma	6 (8)	2 (10)	2 (14.2)
MCL	1 (1.3)	1 (5)	3 (21.4)
BL	1 (1.3)
PL	1 (1.3)
Unclassified			2 (14.2)
T-cell lymphoma					5 (4.6)
EATCL		3 (15)
ALCL		1 (5)
Unclassified	1 (1.3)

DLBCL: Diffuse large B-cell lymphoma; MALT: Mucosa-associated lymphoid tissue B-cell; MCL: Mantle cell lymphoma; BL: Burkitt lymphoma; PL: Plasmablastic lymphoma; EATCL: Enteropathy-associated T-cell lymphoma; ALCL: Anaplastic large cell lymphoma.

Table 2 Risk factors associated with overall survival and event-free survival in Primary gastrointestinal lymphoma

Clinical characteristic	Case (n)	OS (%)		EFS (%)
		Univariate analysis 1-year/3-year/ 5-year, P value	Multivariate analysis, P value	P value
Age (years)		0.529	-	0.546
< 60	28	64.3/56/56
≥ 60	34	70.4/49.4/49.4
Gender		0.853	-	0.842
Female	27	54.7/50.2/50.2
Male	35	77.1/61.7/54.5
Cell Fenotype		0.900	-	0.403
B-Cell	60	68.1/56.7/52.2
T-Cell	2	50/50/50
LDH level		0.029	0.085	0.090
< 270	44	77.1/69.3/62.7
≥ 270	18	44.4/27.8/27.8
Surgical treatment		0.002	0.384	0.013
Surgical treatment (-)	52	74.8/63.7/58.6
Surgical treatment (+)	10	30/20/20
Stage group		0.553	-	0.909
I-II	57	68.2/58.1/53.5
IV	5	60/40/40
Performance score		< 0.0001	0.010	0.002
0-1	55	74.4/63.9/59
≥ 2	7	14.3/0/0
IPI score		0.095	-	0.024
0-2	55	68.9/58.4/53.5
≥ 3	5	40/20/20

OS: Overall survival; EFS: Event-free survival; LDH: Lactate dehydrogenase; IPI: International Prognostic Index.

Table 3 Comparison of clinical characteristics, overall survival, event-free survival, and sites of origin, n (%)

Clinical characteristic	Stomach (n = 43) (69.3%)	Intestinal tract (n = 19) (30.6%)	P value
Age (years)			0.153
< 60	22 (51.2)	6 (31.6)
≥ 60	21 (48.8)	13 (68.4)
Gender			0.687
Female	18 (41.9)	9 (47.4)
Male	25 (58.1)	10 (52.6)
Histologic type			0.522
B-Cell	42 (97.7)	18 (94.7)
T-Cell	1 (2.3)	1 (5.3)
LDH level			0.033
< 270	27 (62.8)	17 (89.5)
≥ 270	16 (37.2)	2 (10.5)
Stage group			0.638
I-II	40 (93)	17 (89.5)
IV	3 (7)	2 (10.5)
Performance score			1.000
0-1	38 (88.4)	17 (89.5)
≥ 2	5 (11.6)	2 (10.5)
IPI score			0.666
0-2	39 (90.7)	16 (84.2)
≥ 3	4 (9.3)	1 (5.3)
OS (%)			0.531
1-year/3-year/5-year	67.4/56.6/53.4	67.7/56.4/49.3
EFS (%)			0.720
1-year/3-year/5-year	80.2/63.9/56.8	79.6/48.3/48.3

OS: Overall survival; EFS: Event-free survival; LDH: Lactate dehydrogenase; IPI: International Prognostic Index.